Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein–Barr virus-positive diffuse large B-cell lymphoma - Scorecard - MDSpire
Clinical Scorecard: Case Study: Challenges in Diagnosis and Biomarker-Driven Treatment of CD20-Negative Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma
At a Glance
Category
Detail
Condition
CD20-Negative Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma
Key Mechanisms
Characterized by EBER positivity and absence of CD20 expression, complicating diagnosis and treatment.
Target Population
Patients with CD20-negative EBV+ DLBCL, NOS.
Care Setting
Oncology and hematology clinical settings.
Key Highlights
EBV+ DLBCL, NOS, lacking CD20 expression complicates diagnosis and therapy.
Integrated immunophenotypic and molecular analyses are crucial for accurate diagnosis.
Biomarker-driven treatment led to a complete metabolic response.
The case emphasizes the need for CD20-independent treatment strategies.
Guideline-Based Recommendations
Diagnosis
Utilize integrated immunohistochemistry and molecular analysis for accurate lineage assignment.
Management
Consider CD30-targeted therapy and PD-1 blockade in treatment.
Monitoring & Follow-up
Regular assessment of EBV-DNA levels and imaging for disease progression.
Risks
Potential for misdiagnosis due to absence of conventional B-cell markers.
Patient & Prescribing Data
76-year-old male with CD20-negative EBV+ DLBCL, NOS.
Received Brentuximab Vedotin plus CHP chemotherapy and Tislelizumab for 6 cycles.
Clinical Best Practices
Perform repeat biopsies when initial diagnoses are uncertain.
Incorporate biomarker analysis in treatment planning for lymphomas.
